Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: RPL26L1

Gene summary for RPL26L1

Gene summary.

Gene information	Species	Human
	Gene symbol	RPL26L1
	Gene ID	51121
	Gene name	ribosomal protein L26 like 1
	Gene Alias	RPL26P1
	Cytomap	5q35.1
	Gene Type	protein-coding
	GO ID	GO:0002181
	UniProtAcc	Q9UNX3

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
51121	RPL26L1	LZE2T	Human	Esophagus	ESCC	1.44e-02	7.69e-01	0.082
51121	RPL26L1	LZE3D	Human	Esophagus	HGIN	2.59e-03	7.61e-01	0.0668
51121	RPL26L1	LZE4T	Human	Esophagus	ESCC	1.34e-10	3.79e-01	0.0811
51121	RPL26L1	LZE7T	Human	Esophagus	ESCC	1.99e-08	4.63e-01	0.0667
51121	RPL26L1	LZE8T	Human	Esophagus	ESCC	4.50e-06	3.75e-01	0.067
51121	RPL26L1	LZE20T	Human	Esophagus	ESCC	1.97e-13	3.86e-01	0.0662
51121	RPL26L1	LZE24T	Human	Esophagus	ESCC	2.30e-26	7.24e-01	0.0596
51121	RPL26L1	LZE21T	Human	Esophagus	ESCC	1.15e-04	4.98e-01	0.0655
51121	RPL26L1	LZE6T	Human	Esophagus	ESCC	3.03e-18	7.39e-01	0.0845
51121	RPL26L1	P1T-E	Human	Esophagus	ESCC	1.95e-13	5.41e-01	0.0875
51121	RPL26L1	P2T-E	Human	Esophagus	ESCC	1.24e-64	1.10e+00	0.1177
51121	RPL26L1	P4T-E	Human	Esophagus	ESCC	2.99e-37	9.83e-01	0.1323
51121	RPL26L1	P5T-E	Human	Esophagus	ESCC	6.47e-64	1.09e+00	0.1327
51121	RPL26L1	P8T-E	Human	Esophagus	ESCC	1.80e-22	4.40e-01	0.0889
51121	RPL26L1	P9T-E	Human	Esophagus	ESCC	4.17e-13	3.65e-01	0.1131
51121	RPL26L1	P10T-E	Human	Esophagus	ESCC	1.88e-42	6.14e-01	0.116
51121	RPL26L1	P11T-E	Human	Esophagus	ESCC	1.97e-26	1.03e+00	0.1426
51121	RPL26L1	P12T-E	Human	Esophagus	ESCC	1.06e-61	1.03e+00	0.1122
51121	RPL26L1	P15T-E	Human	Esophagus	ESCC	3.66e-40	8.34e-01	0.1149
51121	RPL26L1	P16T-E	Human	Esophagus	ESCC	6.45e-47	7.63e-01	0.1153

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0022613111	Esophagus	ESCC	ribonucleoprotein complex biogenesis	365/8552	463/18723	1.74e-49	1.11e-45	365
GO:0042254111	Esophagus	ESCC	ribosome biogenesis	252/8552	299/18723	3.27e-44	1.04e-40	252
GO:0002181111	Esophagus	ESCC	cytoplasmic translation	135/8552	148/18723	4.17e-32	2.65e-29	135
GO:0042273111	Esophagus	ESCC	ribosomal large subunit biogenesis	65/8552	72/18723	1.53e-15	9.82e-14	65
GO:000218112	Liver	Cirrhotic	cytoplasmic translation	120/4634	148/18723	2.95e-47	1.85e-43	120
GO:002261312	Liver	Cirrhotic	ribonucleoprotein complex biogenesis	231/4634	463/18723	3.28e-32	6.86e-29	231
GO:004225412	Liver	Cirrhotic	ribosome biogenesis	154/4634	299/18723	1.18e-23	6.72e-21	154
GO:004227312	Liver	Cirrhotic	ribosomal large subunit biogenesis	47/4634	72/18723	4.20e-13	3.29e-11	47
GO:002261322	Liver	HCC	ribonucleoprotein complex biogenesis	355/7958	463/18723	7.76e-52	4.92e-48	355
GO:004225422	Liver	HCC	ribosome biogenesis	246/7958	299/18723	4.99e-46	1.58e-42	246
GO:000218122	Liver	HCC	cytoplasmic translation	132/7958	148/18723	9.09e-33	5.76e-30	132
GO:004227322	Liver	HCC	ribosomal large subunit biogenesis	64/7958	72/18723	2.31e-16	2.03e-14	64
GO:002261320	Oral cavity	OSCC	ribonucleoprotein complex biogenesis	333/7305	463/18723	8.28e-48	5.24e-44	333
GO:004225420	Oral cavity	OSCC	ribosome biogenesis	230/7305	299/18723	3.22e-41	6.80e-38	230
GO:000218120	Oral cavity	OSCC	cytoplasmic translation	133/7305	148/18723	1.94e-38	2.46e-35	133
GO:004227320	Oral cavity	OSCC	ribosomal large subunit biogenesis	61/7305	72/18723	1.52e-15	1.06e-13	61
GO:0002181110	Oral cavity	LP	cytoplasmic translation	124/4623	148/18723	5.09e-52	3.19e-48	124
GO:0022613110	Oral cavity	LP	ribonucleoprotein complex biogenesis	259/4623	463/18723	7.20e-48	2.25e-44	259
GO:0042254110	Oral cavity	LP	ribosome biogenesis	173/4623	299/18723	8.97e-35	1.41e-31	173
GO:0042273110	Oral cavity	LP	ribosomal large subunit biogenesis	53/4623	72/18723	3.25e-18	5.82e-16	53

Page: 1 2

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa03010211	Esophagus	ESCC	Ribosome	129/4205	167/8465	1.43e-13	3.43e-12	1.75e-12	129
hsa05171211	Esophagus	ESCC	Coronavirus disease - COVID-19	156/4205	232/8465	3.18e-08	2.68e-07	1.37e-07	156
hsa03010310	Esophagus	ESCC	Ribosome	129/4205	167/8465	1.43e-13	3.43e-12	1.75e-12	129
hsa05171310	Esophagus	ESCC	Coronavirus disease - COVID-19	156/4205	232/8465	3.18e-08	2.68e-07	1.37e-07	156
hsa0301022	Liver	Cirrhotic	Ribosome	127/2530	167/8465	2.12e-35	7.06e-33	4.35e-33	127
hsa0517122	Liver	Cirrhotic	Coronavirus disease - COVID-19	136/2530	232/8465	3.28e-20	1.82e-18	1.12e-18	136
hsa0301032	Liver	Cirrhotic	Ribosome	127/2530	167/8465	2.12e-35	7.06e-33	4.35e-33	127
hsa0517132	Liver	Cirrhotic	Coronavirus disease - COVID-19	136/2530	232/8465	3.28e-20	1.82e-18	1.12e-18	136
hsa0301042	Liver	HCC	Ribosome	128/4020	167/8465	7.32e-15	2.23e-13	1.24e-13	128
hsa0517142	Liver	HCC	Coronavirus disease - COVID-19	167/4020	232/8465	1.50e-14	4.19e-13	2.33e-13	167
hsa0301052	Liver	HCC	Ribosome	128/4020	167/8465	7.32e-15	2.23e-13	1.24e-13	128
hsa0517152	Liver	HCC	Coronavirus disease - COVID-19	167/4020	232/8465	1.50e-14	4.19e-13	2.33e-13	167
hsa0301030	Oral cavity	OSCC	Ribosome	128/3704	167/8465	2.42e-18	1.62e-16	8.25e-17	128
hsa0517130	Oral cavity	OSCC	Coronavirus disease - COVID-19	156/3704	232/8465	2.30e-13	5.14e-12	2.62e-12	156
hsa03010114	Oral cavity	OSCC	Ribosome	128/3704	167/8465	2.42e-18	1.62e-16	8.25e-17	128
hsa05171114	Oral cavity	OSCC	Coronavirus disease - COVID-19	156/3704	232/8465	2.30e-13	5.14e-12	2.62e-12	156
hsa03010210	Oral cavity	LP	Ribosome	127/2418	167/8465	1.22e-37	4.05e-35	2.61e-35	127
hsa05171210	Oral cavity	LP	Coronavirus disease - COVID-19	128/2418	232/8465	7.04e-18	2.34e-16	1.51e-16	128
hsa0301038	Oral cavity	LP	Ribosome	127/2418	167/8465	1.22e-37	4.05e-35	2.61e-35	127
hsa0517138	Oral cavity	LP	Coronavirus disease - COVID-19	128/2418	232/8465	7.04e-18	2.34e-16	1.51e-16	128

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

RPL26L1

SNV

Missense_Mutation

c.228N>T

p.Lys76Asn

p.K76N

Q9UNX3

protein_coding

deleterious(0.01)

probably_damaging(0.98)

TCGA-F5-6814-01

Colorectum

rectum adenocarcinoma

Male

<65

I/II

Unknown

RPL26L1

SNV

Missense_Mutation

c.228N>T

p.Lys76Asn

p.K76N

Q9UNX3

protein_coding

deleterious(0.01)

probably_damaging(0.98)

TCGA-AX-A0J0-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

RPL26L1

SNV

Missense_Mutation

c.260N>A

p.Arg87His

p.R87H

Q9UNX3

protein_coding

tolerated(0.07)

benign(0.021)

TCGA-B5-A11E-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

RPL26L1

SNV

Missense_Mutation

rs773507352

c.250N>T

p.Arg84Trp

p.R84W

Q9UNX3

protein_coding

tolerated(0.1)

benign(0.007)

TCGA-B5-A3FC-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

RPL26L1

SNV

Missense_Mutation

novel

c.423N>T

p.Glu141Asp

p.E141D

Q9UNX3

protein_coding

tolerated(0.1)

benign(0.005)

TCGA-B5-A3FC-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

RPL26L1

SNV

Missense_Mutation

novel

c.258G>T

p.Gln86His

p.Q86H

Q9UNX3

protein_coding

tolerated(0.06)

benign(0.019)

TCGA-BG-A222-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

RPL26L1

SNV

Missense_Mutation

c.247G>A

p.Glu83Lys

p.E83K

Q9UNX3

protein_coding

tolerated(0.05)

possibly_damaging(0.793)

TCGA-BS-A0U8-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

RPL26L1

SNV

Missense_Mutation

rs779289794

c.355N>A

p.Leu119Ile

p.L119I

Q9UNX3

protein_coding

tolerated(0.12)

benign(0.102)

TCGA-BS-A0UV-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

RPL26L1

SNV

Missense_Mutation

rs767751234

c.176N>A

p.Arg59Gln

p.R59Q

Q9UNX3

protein_coding

tolerated(0.09)

benign(0.116)

TCGA-E6-A1LX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

RPL26L1

SNV

Missense_Mutation

novel

c.351N>C

p.Lys117Asn

p.K117N

Q9UNX3

protein_coding

tolerated(0.12)

benign(0.021)

TCGA-FI-A2D5-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatinum

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1